MintNeuro’s Post

Amber Tx successfully closes a $100 million Series A financing to advance breakthrough Amber-UI neuromodulation therapy for mixed urinary incontinence towards US FDA approval. US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI). Amber-UI has the unique potential to treat the millions of women who suffer from both urge and stress incontinence with a singular adaptive therapy. Read the full press release and learn more about our therapy approach on our website: https://lnkd.in/eZ7XthCy